Campbell & CO Investment Adviser LLC Macrogenics Inc Transaction History

Campbell & CO Investment Adviser LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$9.77 - $21.47 $733,629 - $1.61 Million	-75,090 Reduced 80.74%	17,915 $263,000
Q4 2023 Feb 13, 2024	BUY	$4.48 - $10.11 $416,662 - $940,280	93,005 New	93,005 $894,000
Q2 2022 Aug 09, 2022	SELL	$2.25 - $9.99 $67,398 - $299,250	-29,955 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$8.12 - $16.9 $243,234 - $506,239	29,955 New	29,955 $264,000
Q4 2019 Jan 23, 2020	SELL	$7.95 - $12.27 $214,928 - $331,719	-27,035 Closed	0 $0
Q3 2019 Oct 16, 2019	BUY	$12.44 - $17.48 $336,315 - $472,571	27,035 New	27,035 $345,000
Q2 2019 Jul 10, 2019	SELL	$14.51 - $19.71 $262,950 - $357,184	-18,122 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$11.11 - $25.6 $201,335 - $463,923	18,122 New	18,122 $326,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $202M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.